The Cuban CIMAB S.A. enterprise and Neuronic Mexicana S.A. de C.V. announced this Tuesday the constitution of the IncuBIO S.A. joint venture in the Mariel Special Development Zone.
According to a note published on the CIMAB S.A. website, the new enterprise aims to attract risk capital.
Future investors will have the opportunity to acquire shares of IncuBIO S.A. and to contribute to increasing the value of products by financing proof-of-concept clinical trials in developed country markets, the text says.
To do this, it stressed, it has an exclusive license for the development and commercialization of innovative biotechnological products, including NeuroEPO, one of the most promising of the Center for Molecular Immunology (CIM).
It is an intranasal formulation of recombinant human erythropoietin, with a low content of sialic acid, which is currently being clinically evaluated in Cuba to treat neurodegenerative diseases such as Alzheimer’s, Parkinson’s and Ataxia.
The note also pointed out that during the recently completed proof-of-concept trial, NeuroEPO showed evidence of acting as a homeostatic regulator of the brain and improving cognitive decline in patients with Alzheimer’s.
CIMAB S.A. is in charge of the development and administration of businesses through its direct participation in international alliances involving the main biotechnological products of the CIM.
With the incorporation of IncuBIO, CIMAB is a shareholder of five joint ventures in China, Thailand, Singapore and Cuba. Neuronic Mexicana S.A. de C.V. is an entity established in 1992 to commercialize biopharmaceutical products and medical equipment.
